- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/42 - Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
Patent holdings for IPC class C07D 213/42
Total number of patents in this class: 137
10-year publication summary
|
11
|
7
|
11
|
8
|
10
|
3
|
7
|
5
|
8
|
1
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4840 |
8 |
| F. Hoffmann-La Roche AG | 7946 |
4 |
| Takeda Pharmaceutical Company Limited | 2704 |
4 |
| The University of Melbourne | 543 |
4 |
| Grey Wolf Therapeutics Limited | 16 |
4 |
| The Johns Hopkins University | 5730 |
3 |
| Ranbaxy Laboratories Limited | 286 |
3 |
| Gliapharm SA | 18 |
3 |
| Mitsui Chemicals Crop & Life Solutions,Inc. | 164 |
3 |
| BASF SE | 21036 |
2 |
| Janssen Pharmaceutica N.V. | 3367 |
2 |
| Massachusetts Institute of Technology | 10121 |
2 |
| Artizan Biosciences, Inc. | 10 |
2 |
| Concert Pharmaceuticals, Inc. | 246 |
2 |
| Council of Scientific and Industrial Research | 599 |
2 |
| The Governing Council of The University of Toronto, | 1490 |
2 |
| Jazz Pharmaceuticals Ireland Limited | 141 |
2 |
| Kanto Kagaku Kabushiki Kaisha | 88 |
2 |
| Nissan Chemical Industries, Ltd. | 1704 |
2 |
| Oryzon Genomics S.A. | 109 |
2 |
| Other owners | 79 |